Innovation  Saving  Lives

The Latest from OBD

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington’s disease.

Salter, M., et. al.,
F1000Research 2018, 7:1757

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen, K.

Chromosome conformation signatures as a clinical tool for diagnosis, prognosis and disease understanding in ALS

Salter, M., et. al.,

White blood cells from Prostate cancer patients carry distinct Chromosome Conformations.

Pchejetski, D., et. al.
J of Urology

Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis.

Carini et. al.
J Transl Med

A chromosomal conformation signature for a priori prediction of ALS progression subtypes.

Salter, et. al.,
F1000 Research

Glycaemic progression study among population in Penang, Malaysia.

Patel, JS, et. al.,
Diabetes Asia 2017 Conference

A Prospective Study of Two Distinct Epigenetic Signatures for ALS Diagnosis and Prognosis.

Westra, W, et. al.,
16th Annual Northeast Amyotrophic Lateral Sclerosis Meeting

Epigenetic signatures and early detection of neurodegenerative diseases: Development of stratifying biomarker for ALS in Asian cohorts.

Lim, CR, et. al.,
World Congress of Neurology